An overview of key considerations shaping the BGM and CGM decision, why both often coexist in trials today, and how eCOA platforms play a critical role in supporting this data collection at scale.
Karl McEvoy, PhD, and Aubrey Verna
Advertisement
Articles by Karl McEvoy, PhD, and Aubrey Verna
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue
2
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
3
How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials
4
Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices
5